fda glp-1 warning letters september 2025 takes aim at telehealth companies for promoting unofficial weight loss drug dupes Beyond the Headlines: FDA Warning
Description
( 10.2337/db16-1206) [DOI] [PMC free article] [PubMed] [Google Scholar] Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 31.Drucker DJ
Libraries were quantified with NuQuant, quality checked using a TapeStation instrument (Agilent Technologies) and subjected to 52 bp paired-end sequencing on the NovaSeq 6000 system (Illumina)

The new study found that GLP-1 drugs appear to double the risk for developing neovascular age-related macular degeneration (nAMD), a condition that causes vision loss

Additionally, these agents demonstrate remarkable cardiovascular risk reduction in high-risk type 2 diabetes patients

The label itself makes an important admission: it hasnt been established that appetite suppression is its only effect in obesity, because it also produces other central nervous system actions
